RxNews Recap for Friday 12-04-09 Print E-mail
By Mary Davila   
Friday, 04 December 2009 19:37

Below is a list of the companies that made news in the healthcare sector on Friday, December 04, 2009.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Biomagnetics Diagnostics Corp., (PinkSheets:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection provides the following recap of yesterday's investor conference call, which discussed the Company’s acquisition of intellectual property rights from Los Alamos National Security and how the Company plans to utilize this intellectual property for the development of a revolutionary, handheld integrated optical biosensor capable of highly accurate and rapid HIV/AIDS, malaria, tuberculosis, and other pathogen detection and disease diagnosis.

BioTime, Inc. (NYSE Amex:BTIM) Chief Executive Officer Michael D. West, Ph.D. will ring The Opening Bell at the New York Stock Exchange at 9:30 a.m. Eastern on Tuesday, December 8, 2009.

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) announced that Janssen-Cilag has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for paliperidone palmitate for the treatment of Schizophrenia.

Health Sciences Group, Inc. (PINKSHEETS:HESG) would like to announce that it is in strong negotiations to acquire a minority stake in two separate Montana-based marijuana growing, distribution and care giving operations.

Hospira, Inc. (NYSE:HSP), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL VisIV(TM) containers for intravenous (I.V.) medications and solutions, and now offers a complete size range (50 mL to 1 L) of the award-winning, environmentally responsible VisIV product.

ICON plc, (NASDAQ:ICLR), today announced it has received a warning letter from the U.S. Food and Drug Administration (FDA) regarding clinical study management services provided by the company to one of its clients in relation to two studies conducted between 2004 and 2006.

Orthofix International (NASDAQ: OFIX) announced today that its sports medicine division, BREG, has expanded its successful line of FUSION® functional knee braces by introducing the FUSION® Lateral OA Brace, which features an ultra-thin low-profile hinge designed for individuals suffering from lateral compartment osteoarthritis (OA).

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast.Principal investigators will discuss the data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting.

PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today the presentation of new data from the Company's anthrax vaccine program showing that its lyophilized recombinant Protective Antigen (rPA) based anthrax vaccine is structurally stable and potent after 16 months at various temperatures up to and including 55 degrees.

St. Jude Medical, Inc. (NYSE:STJ) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy.

Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY) announced today that the Company has completed its evaluation of its opportunities to develop prescription pharmaceutical and OTC products and has concluded that it is in its best interests to focus primarily on the OTC/Personal Care marketplace, which may include but are not limited to its Cold-EEZE® and Kids-EEZE® brands, as well as other homeopathic, dietary supplement, cosmetic, cosmeceutical, first aid, functional food and beverage products.

Unilife Medical Solutions Limited (ASX:UNI) (PINKSHEETS: UNIFF) today announced that a video of the recent Annual General Meeting ("AGM") held in Sydney on November 30, 2009 had been placed onto the Company's website.

Watson Pharmaceuticals, Inc. (NYSE:WPI), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its 8mg ramelteon tablets prior to the expiration of a patent owned by Takeda Pharmaceutical Company Limited.Watson's 8mg ramelteon tablet product is a generic version of Takeda's Rozerem®, which is indicated for the treatment of insomnia characterized by difficulty with sleep onset.

ZOLL Medical Corporation (NasdaqGS: ZOLL) announced today that it will participate in a conference call hosted by SunTrust Robinson Humphrey on Thursday, December 10, 2009 at 10:30am EST to discuss the LifeVest® wearable defibrillator business.

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced the pricing of its previously announced underwritten public offering of 15,484,000 shares of its common stock and warrants to purchase 7,742,000 shares of its common stock at a public offering price of $3.10 per unit.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus